Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized extended interval dosing of natalizumab in relapsing-remitting multiple sclerosis
NL-OMON54545Phase 4Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of natalizumab in multiple sclerosis (MS) (3 arms), sponsored by Vrije University Medical Center. Primary endpoint: Radiological disease activity after two years. Started Feb 2020; status: recruiting.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON54545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54545.